Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer

Click here to sign up to receive our monthly PubMed review in your inbox!

Literature Review, May 2018


Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKKα/NF-κB pathway. Ji DG1, Guan LY1, Luo X2, Ma F3, Yang B4, Liu HY1. Biochem Biophys Res Commun. 2018 Jun 18;501(1):33-40. doi: 10.1016/j.bbrc.2018.04.116. Epub 2018 May 7.


Increased infiltration of macrophages to radioresistant lung cancer cells contributes to the development of the additional resistance of tumor cells to the cytotoxic effects of NK cells.

Shen M1, Chen Y2, Xu L2, Zhu R2, Xue X2, Tsai Y1, Keng PC1, Lee SO1, Chen Y1. Int J Oncol. 2018 Jul;53(1):317-328. doi: 10.3892/ijo.2018.4394. Epub 2018 May 4.


Radiation followed by OX40 stimulation drives local and abscopal antitumor effects in an anti-PD1-resistant lung tumor model. Niknam S1, Barsoumian HB2, Schoenhals JE1, et al. Clin Cancer Res. 2018 May 21. pii: clincanres.3279.2017. doi: 10.1158/1078-0432.CCR-17-3279. [Epub ahead of print]


Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis. Feng SQ1, Wang GJ1, Zhang JW1, Xie Y1, Sun RB1, Fei F1, Huang JQ1, Wang Y1, Aa JY1, Zhou F1. Acta Pharmacol Sin. 2018 May 17. doi: 10.1038/aps.2018.16. [Epub ahead of print]


Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.

Codony-Servat J1, García-Roman S1, Molina-Vila MÁ2, et al. J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30592-6. doi: 10.1016/j.jtho.2018.04.030. [Epub ahead of print]


Regional lymph node sampling in lung carcinoma: a single institutional and national database comparison. Bosch DE1, Farjah F2, Wood DE2, Schmidt RA3. Hum Pathol. 2018 May;75:55-62. doi: 10.1016/j.humpath.2018.02.002. Epub 2018 Feb 13.


Use of circulating tumor cells in prospective clinical trials for NSCLC patients – standardization of the pre-analytical conditions. Ilie M1,2,3, Hofman V1,2,3, Leroy S4, et al. Clin Chem Lab Med. 2018 May 24;56(6):980-989. doi: 10.1515/cclm-2017-0764.


PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project. Tsao MS1, Kerr KM2, Kockx M3, et al. J Thorac Oncol. 2018 May 22. pii: S1556-0864(18)30626-9. doi: 10.1016/j.jtho.2018.05.013. [Epub ahead of print]


MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial. Bousema JE1,2, Dijkgraaf MGW2,3, Papen-Botterhuis NE1, et al. BMC Surg. 2018 May 18;18(1):27. doi: 10.1186/s12893-018-0359-6.


Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

Kim TO1, Oh IJ1,2, Kho BG1, et al. Thorac Cancer. 2018 May 14. doi: 10.1111/1759-7714.12762. [Epub ahead of print]


Medical Care Costs Were Similar Across the Low-dose Computed Tomography and Chest X-Ray Arms of the National Lung Screening Trial Despite Different Rates of Significant Incidental Findings. Gareen IF1, Black WC2, Tosteson TD3, Wang Q4, Sicks JD5, Tosteson ANA6. Med Care. 2018 May;56(5):403-409. doi: 10.1097/MLR.0000000000000900.


Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer. Raghunathan R1, Cease K1, Troeschel S1, Zhao L2, Gross M3, Chen G4, Chopra V1, Ramnath N1. Am J Clin Oncol. 2018 May;41(5):513-518. doi: 10.1097/COC.0000000000000316.


New subsolid pulmonary nodules in lung cancer screening: a brief report of the NELSON trial.

Walter JE1, Heuvelmans MA2, Yousaf-Khan U3, et al. J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30605-1. doi: 10.1016/j.jtho.2018.05.006. [Epub ahead of print]


The Feasibility of Thoracoscopic Left Pneumonectomy. Xu H1, Zhang L1. Thorac Cardiovasc Surg. 2018 May 1. doi: 10.1055/s-0038-1642618. [Epub ahead of print]


Risk Factors of Recurrence in Patients With Clinical Stage IA Adenocarcinoma Presented as Ground-Glass Nodule. Su H1, Dai C1, Xie H2, Ren Y1, She Y1, Kadeer X1, Xie D1, Zheng H1, Jiang G1, Chen C3. Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30102-5. doi: 10.1016/j.cllc.2018.04.020. [Epub ahead of print]


American Society of Anesthesiologists physical status facilitates risk stratification of elderly patients undergoing thoracoscopic lobectomy. Zhang R1, Kyriss T1, Dippon J2, Hansen M3, Boedeker E1, Friedel G1. Eur J Cardiothorac Surg. 2018 May 1;53(5):973-979. doi: 10.1093/ejcts/ezx436.


Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. Reynolds C1,2, Masters ET3, Black-Shinn J4, Boyd M5, Mardekian J6, Espirito JL7, Chioda M8. J Clin Med. 2018 May 29;7(6). pii: E129. doi: 10.3390/jcm7060129.


Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). Chae YK1,2,3, Arya A4, Iams W5, Cruz MR4, Chandra S4,6,5, Choi J6,5, Giles F4,6,5. J Immunother Cancer. 2018 May 16;6(1):39. doi: 10.1186/s40425-018-0349-3.


Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer. Gettinger S1, Hellmann MD2, Chow LQM3, et al. J Thorac Oncol. 2018 May 23. pii: S1556-0864(18)30628-2. doi: 10.1016/j.jtho.2018.05.015. [Epub ahead of print]


Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. Leonardi GC1, Gainor JF1, Altan M1, et al. J Clin Oncol. 2018 May 10:JCO2017770305. doi: 10.1200/JCO.2017.77.0305. [Epub ahead of print]


Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. Solomon BJ1, Kim DW1, Wu YL1, et al. J Clin Oncol. 2018 May 16:JCO2017774794. doi: 10.1200/JCO.2017.77.4794. [Epub ahead of print]


Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. Morcos PN1, Nueesch E2, Jaminion F3, Guerini E3, Hsu JC4, Bordogna W2, Balas B2, Mercier F3. Cancer Chemother Pharmacol. 2018 May 10. doi: 10.1007/s00280-018-3597-5. [Epub ahead of print]


Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. O’Connor JM1,2, Fessele KL3, Steiner J3, et al. JAMA Oncol. 2018 May 10:e180798. doi: 10.1001/jamaoncol.2018.0798. [Epub ahead of print]


FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer. Spigel DR1, Chaft JE2, Gettinger S3, et al. J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30603-8. doi: 10.1016/j.jtho.2018.05.004. [Epub ahead of print]


Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial. Nakao A1, Uchino J2, Igata F1, et al. Invest New Drugs. 2018 May 30. doi: 10.1007/s10637-018-0617-6. [Epub ahead of print]


nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial. Gridelli C1, Chen T2, Ko A2, O’Brien ME3, Ong TJ4, Socinski MA5, Postmus PE6. Drug Des Devel Ther. 2018 May 24;12:1445-1451. doi: 10.2147/DDDT.S155750. eCollection 2018.


Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment. Jakobsen JN1, Santoni-Rugiu E2, Grauslund M2, Melchior L2, Sørensen JB1. Oncotarget. 2018 May 25;9(40):26195-26208. doi: 10.18632/oncotarget.25490. eCollection 2018 May 25.


Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin. Hirsh V1, Wan Y2, Lin FJ2, Margunato-Debay S3, Ong TJ3, Botteman M2, Langer C4. Clin Lung Cancer. 2018 May 7. pii: S1525-7304(18)30105-0. doi: 10.1016/j.cllc.2018.04.023. [Epub ahead of print]


Combination Immunotherapy in Non-small Cell Lung Cancer. Marmarelis ME1, Aggarwal C2,3. Curr Oncol Rep. 2018 May 8;20(7):55. doi: 10.1007/s11912-018-0697-7.


Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer. Koba T1,2, Minami S1, Nishijima-Futami Y1,2, et al. Cancer Chemother Pharmacol. 2018 May 4. doi: 10.1007/s00280-018-3598-4. [Epub ahead of print]


Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study. De Ruysscher D1, Dingemans AC1, Praag J1, et al. J Clin Oncol. 2018 May 22:JCO2017775817. doi: 10.1200/JCO.2017.77.5817. [Epub ahead of print]


Changes in Regional Ventilation During Treatment and Dosimetric Advantages of CT Ventilation Image Guided Radiation Therapy for Locally Advanced Lung Cancer. Yamamoto T1, Kabus S2, Bal M3, Bzdusek K4, Keall PJ5, Wright C6, Benedict SH6, Daly ME6. Int J Radiat Oncol Biol Phys. 2018 May 4. pii: S0360-3016(18)30741-7. doi: 10.1016/j.ijrobp.2018.04.063. [Epub ahead of print]


Three- Versus Five-Fraction Regimens of Stereotactic Body Radiotherapy for Peripheral Early-Stage Non-Small-Cell Lung Cancer: A Two-Institution Propensity Score-Matched Analysis. Ma SJ1, Cummings M2, Serra LM1, et al. Clin Lung Cancer. 2018 May;19(3):e297-e302. doi: 10.1016/j.cllc.2017.11.007. Epub 2017 Nov 26.


Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. Timmerman RD1,2, Paulus R3, Pass HI4, et al. JAMA Oncol. 2018 May 31. doi: 10.1001/jamaoncol.2018.1251. [Epub ahead of print]


Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer. Brandt WS1, Yan W1, Leeman JE2, et al. Ann Thorac Surg. 2018 May 25. pii: S0003-4975(18)30709-4. doi: 10.1016/j.athoracsur.2018.04.064. [Epub ahead of print]


Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer. Yang J1,2, Xu T1, Gomez DR1, et al. Cancer Med. 2018 May 9. doi: 10.1002/cam4.1349. [Epub ahead of print]


Virtual Bronchoscopy-Guided Treatment Planning to Map and Mitigate Radiation-Induced Airway Injury in Lung SAbR. Kazemzadeh N1, Modiri A1, Samanta S1, et al. Int J Radiat Oncol Biol Phys. 2018 May 2. pii: S0360-3016(18)30738-7. doi: 10.1016/j.ijrobp.2018.04.060. [Epub ahead of print]


Adding Radiation to Adjuvant Chemotherapy Does Not Improve Survival of Patients with N2 Lung Cancer. Drake JA1, Portnoy DC2, Tauer K2, Weksler B3. Ann Thorac Surg. 2018 May 29. pii: S0003-4975(18)30720-3. doi: 10.1016/j.athoracsur.2018.04.074. [Epub ahead of print]


Evaluation of functionally weighted dose-volume parameters for thoracic stereotactic ablative radiotherapy (SABR) using CT ventilation. Kanai T1, Kadoya N2, Nakajima Y3, et al. Phys Med. 2018 May;49:47-51. doi: 10.1016/j.ejmp.2018.05.001. Epub 2018 May 8.


Pilot Study of the Safety and Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumors. Mitsuyoshi T1, Matsuo Y2, Shintani T1, Iizuka Y1, Ueki N3, Nakamura M1, Mizowaki T1. Clin Lung Cancer. 2018 May;19(3):e287-e296. doi: 10.1016/j.cllc.2017.11.008. Epub 2017 Nov 28.


Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. Salhab M1, Migdady Y2, Donahue M3, Xiong Y4, Dresser K4, Walsh W3, Chen BJ4, Liebmann J5. J Immunother Cancer. 2018 May 29;6(1):42. doi: 10.1186/s40425-018-0359-1.


Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC).

Gadgeel SM1, Pennell NA2, Fidler MJ3, et al. J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30600-2. doi: 10.1016/j.jtho.2018.05.002. [Epub ahead of print]


Prophylactic Cranial Irradiation in Extensive Stage Small Cell Lung Cancer: Outcomes at a Comprehensive Cancer Centre. Bang A1, Kendal WS1, Laurie SA2, Cook G1, MacRae RM3. Int J Radiat Oncol Biol Phys. 2018 May 1. pii: S0360-3016(18)30736-3. doi: 10.1016/j.ijrobp.2018.04.058. [Epub ahead of print]


Timing of Thoracic Radiation Therapy With Chemotherapy in Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Current Practice Patterns.

Farrell MJ1, Yahya JB2, Degnin C2, et al. Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30089-5. doi: 10.1016/j.cllc.2018.04.007. [Epub ahead of print]


Early versus late prophylactic cranial irradiation in patients with extensive small cell lung cancer.

Chen Y1, Li J2, Zhang Y3, Hu Y2, Zhang G2, Yan X2, Lin Z2, Zhao Z4, Jiao S5,6. Strahlenther Onkol. 2018 May 17. doi: 10.1007/s00066-018-1307-1. [Epub ahead of print]


Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis. Wen P1, Chidanguro T1, Shi Z2, Gu H1, Wang N1, Wang T1, Li Y3, Gao J3. Mol Med Rep. 2018 May 29. doi: 10.3892/mmr.2018.9095. [Epub ahead of print]


Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.

Saito M1,2,3, Shiraishi K1, Goto A4, Suzuki H3, Kohno T1, Kono K2. Jpn J Clin Oncol. 2018 May 14. doi: 10.1093/jjco/hyy068. [Epub ahead of print]


The effect of early versus delayed radiation therapy on length of hospital stay in the palliative setting. Cushman TR1, Shirvani S2, Khan M2, Kumar R3. Ann Palliat Med. 2018 May 28. pii: apm.2018.05.07. doi: 10.21037/apm.2018.05.07. [Epub ahead of print]


Using patient-reported outcome measures to deliver enhanced supportive care to people with lung cancer: feasibility and acceptability of a nurse-led consultation model. Kotronoulas G1, Papadopoulou C2, Simpson MF3, McPhelim J3, Mack L3, Maguire R4. Support Care Cancer. 2018 May 19. doi: 10.1007/s00520-018-4234-x. [Epub ahead of print]


Healthcare experience among older cancer survivors: Analysis of the SEER-CAHPS dataset.

Halpern MT1, Urato MP2, Lines LM3, Cohen JB2, Arora NK4, Kent EE5. J Geriatr Oncol. 2018 May;9(3):194-203. doi: 10.1016/j.jgo.2017.11.005. Epub 2017 Dec 15.


Stress and Quality of Life in Cancer Patients: Medical and Psychological Intervention. Barre PV1, Padmaja G2, Rana S2, Tiamongla2. Indian J Psychol Med. 2018 May-Jun;40(3):232-238. doi: 10.4103/IJPSYM.IJPSYM_512_17.


Long-term low-dose morphine for patients with moderate cancer pain is predominant factor effecting clinically meaningful pain reduction. Zheng RJ1, Fu Y2, Zhu J2, Xu JP3, Xiang QF2, Chen L4, Zhong H2, Li JY5, Yu CH6. Support Care Cancer. 2018 May 31. doi: 10.1007/s00520-018-4282-2. [Epub ahead of print]


Association between patient-reported hearing and visual impairments and functional, psychological, and cognitive status among older adults with cancer. Soto-Perez-de-Celis E1,2, Sun CL1, Tew WP3, et al. Cancer. 2018 May 24. doi: 10.1002/cncr.31540. [Epub ahead of print]


Oral administration of herbal medicines for radiation pneumonitis in lung cancer patients: A systematic review and meta-analysis. Kim KI1,2, Jun JH3,4, Baek H2,5, Kim JH2,5, Lee BJ2, Jung HJ2. PLoS One. 2018 May 30;13(5):e0198015. doi: 10.1371/journal.pone.0198015. eCollection 2018.


The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Zill OA1, Banks KC2, Fairclough SR3, et al. Clin Cancer Res. 2018 May 18. pii: clincanres.3837.2017. doi: 10.1158/1078-0432.CCR-17-3837. [Epub ahead of print]


Racial-Ethnic Disparities in End-of-Life Care Quality among Lung Cancer Patients: A SEER-Medicare-Based Study. Karanth S1, Rajan SS2, Sharma G3, Yamal JM4, Morgan RO1. J Thorac Oncol. 2018 May 10. pii: S1556-0864(18)30540-9. doi: 10.1016/j.jtho.2018.04.014. [Epub ahead of print]


Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study. Bittoni MA1, Arunachalam A2, Li H3, Camacho R3, He J3, Zhong Y3, Lubiniecki GM3, Carbone DP1. Clin Lung Cancer. 2018 May 7. pii: S1525-7304(18)30099-8. doi: 10.1016/j.cllc.2018.04.017. [Epub ahead of print]


Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer. Lu CY1, Loomer S2, Ceccarelli R3, Mazor KM4, Sabin J5, Clayton EW6, Ginsburg GS7, Wu AC8. J Pers Med. 2018 May 16;8(2). pii: E19. doi: 10.3390/jpm8020019.


Closing Knowledge Gaps to Optimize Patient Outcomes and Advance Precision Medicine. Giusti K, Young AQ, Lehrhaupt K1. Cancer J. 2018 May/Jun;24(3):140-147. doi:  10.1097/PPO.0000000000000319.


The impact of self- and physician-administered cancer treatment on work productivity and healthcare utilization. Seabury SA1, Frasco MA2, van Eijndhoven E2, Sison S2, Zacker C3. Res Social Adm Pharm. 2018 May;14(5):434-440. doi: 10.1016/j.sapharm.2017.05.009. Epub 2017 May 22.


Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cronin KA1, Lake AJ2, Scott S1, et al. Cancer. 2018 Jul 1;124(13):2785-2800. doi: 10.1002/cncr.31551. Epub 2018 May 22.


Associations between the smoking-relatedness of a cancer type, cessation attitudes and beliefs, and future abstinence among recent quitters. Martínez Ú1, Brandon TH1,2,3, Sutton SK2,3,4, Simmons VN1,2,3. Psychooncology. 2018 May 21. doi: 10.1002/pon.4774. [Epub ahead of print]


Measuring public knowledge, attitudes, and behaviors related to radon to inform cancer control activities and practices. Neri A1,2, McNaughton C3, Momin B2, Puckett M2, Gallaway MS2. Indoor Air. 2018 Jul;28(4):604-610. doi: 10.1111/ina.12468. Epub 2018 May 14.

Indoor Air. 2018 Jul;28(4):604-610. doi: 10.1111/ina.12468. Epub 2018 May 14.